JPS63216812A - Skin drug for external use - Google Patents

Skin drug for external use

Info

Publication number
JPS63216812A
JPS63216812A JP5127687A JP5127687A JPS63216812A JP S63216812 A JPS63216812 A JP S63216812A JP 5127687 A JP5127687 A JP 5127687A JP 5127687 A JP5127687 A JP 5127687A JP S63216812 A JPS63216812 A JP S63216812A
Authority
JP
Japan
Prior art keywords
formula
skin
amino
expressed
external use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP5127687A
Other languages
Japanese (ja)
Other versions
JPH0692293B2 (en
Inventor
Shinji Yano
真司 矢野
Akira Kawamata
章 川俣
Yoshihiro Minematsu
峰松 義博
Shuichi Akasaki
赤崎 秀一
Mitsuko Zama
座間 美都子
Genji Imokawa
玄爾 芋川
Naotake Takaishi
高石 尚武
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP5127687A priority Critical patent/JPH0692293B2/en
Priority to DE88103177T priority patent/DE3884021T2/en
Priority to DE3854275T priority patent/DE3854275T2/en
Priority to EP88103177A priority patent/EP0282816B1/en
Priority to EP92115766A priority patent/EP0534286B1/en
Priority to ES92115766T priority patent/ES2077948T3/en
Priority to US07/163,835 priority patent/US4985547A/en
Publication of JPS63216812A publication Critical patent/JPS63216812A/en
Priority to US07/546,276 priority patent/US5028416A/en
Priority to US07/584,739 priority patent/US5071971A/en
Publication of JPH0692293B2 publication Critical patent/JPH0692293B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/007Preparations for dry skin

Abstract

PURPOSE:To obtain a skin drug for external use, containing a specific amide derivative, capable of enhancing moisture holding power of keratinous layers and exhibiting excellent improving and preventive effects on roughening of the skin. CONSTITUTION:A skin drug for external use obtained by containing a compound expressed by formula I (R<1> is 10-26C hydrocarbon group; R<2> is 9-25C hydrocar bon group; n is 3-6), e.g. N-(2-hydroxyl-3-hexadecyloxypropyl)-N-3-hydroxy propylhexadacanamide, in an amount of 0.001-50wt.%, preferably 0.1-20wt.% based on the total composition. Effects are further increased by additionally blending 0.01-20wt.% preferably 0.1-5wt.% surfactant, particularly nonionic surfactant. The compound expressed by formula I is prepared by reacting a glycidyl ether expressed by formula II with an amino-alcohol expressed by formula III and then selectively acylating the amino group of the resultant compound expressed by formula IV.

Description

【発明の詳細な説明】 〔産業上の利用分野〕 本発明は皮膚外用剤、更に詳しくは、角質層の水分保持
力を高め、肌あれを改善することができる皮膚外用剤に
関する。
DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to an external skin preparation, and more particularly to an external skin preparation that can improve the moisture retention capacity of the stratum corneum and improve rough skin.

〔従来の技術〕[Conventional technology]

従来、肌にうるおいを与え、肌を柔軟にするには、角質
層の水分が重要であることが知られている。そして、当
該水分の保持は、角質層に含まれている水溶性成分、す
なわち遊離アミノ酸、有機酸、尿素又は無機イオンによ
るものであるとされ、これらの物質は単独であるいは組
合せて薬用皮膚外用剤あるいは化粧料に配合して、肌あ
れの改善又は予防の目的で使用されている。
It has been known that moisture in the stratum corneum is important for moisturizing the skin and making it soft. The retention of moisture is said to be due to water-soluble components contained in the stratum corneum, such as free amino acids, organic acids, urea, or inorganic ions, and these substances may be used alone or in combination in medicated skin preparations. Alternatively, it is used in cosmetics to improve or prevent rough skin.

また、これとは別に水と親和性が高い多くの保湿性物質
が開発され、同様の目的で使用されている。
In addition, many other moisturizing substances that have a high affinity for water have been developed and are used for similar purposes.

〔発明が解決しようとする問題点〕[Problem that the invention seeks to solve]

しかしながら、これらの保湿性物質を皮膚に適用した場
合、その作用は、皮膚角質層上にあって水分を角質に供
給するというもので、しかもその効果は一時的であり、
根本的に角質層の水分保持能力を改善し、肌あれを本質
的に予防あるいは治癒するというものではなかった。
However, when these moisturizing substances are applied to the skin, their action is to supply moisture to the stratum corneum on the stratum corneum, and the effect is temporary.
It did not fundamentally improve the water retention ability of the stratum corneum and essentially prevent or cure rough skin.

〔問題点を解決するための手段〕[Means for solving problems]

斯かる実情において、本発明者らは上記問題点を解決す
べく鋭意研究を行なったところ、今回本発明者らによっ
て初めて合成された次の一般式(I)%式% (式中 R1は炭素数10〜26の直鎖若しくは分岐鎖
の飽和若しくは不飽和の炭化水素基 R2は炭素数9〜
25の直鎖若しくは分岐鎖の飽和若しくは不飽和の炭化
水素基、nは3〜6の数を示す)で表わされるアミド誘
導体が角質層の水分保持能力を根本的に改善する効果を
奏すること、そしてこのアミド誘導体に界面活性剤を併
用するとその効果を更に増大できることを見出し、本発
明を完成した。
Under these circumstances, the present inventors conducted intensive research to solve the above problems, and found that the following general formula (I) % formula % (wherein R1 is carbon 10 to 26 linear or branched saturated or unsaturated hydrocarbon groups R2 has 9 to 26 carbon atoms
The amide derivative represented by 25 linear or branched saturated or unsaturated hydrocarbon groups, where n is a number from 3 to 6) has the effect of fundamentally improving the water retention ability of the stratum corneum; The inventors have also discovered that the effect of this amide derivative can be further enhanced by using a surfactant in combination, and have completed the present invention.

すなわち本発明は、前記式(I)で表わされるアミド誘
導体を含有する皮膚外用材、並びに前記式(りで表わさ
れるアミド誘導体及び界面活性剤を含有する皮膚外用剤
を提供するものである。
That is, the present invention provides an external skin preparation containing the amide derivative represented by the formula (I), and an external skin preparation containing the amide derivative represented by the formula (I) and a surfactant.

本発明に使用される式(I)で表わされるアミド誘導体
は、例えば次に示す反応式に従って製造される。
The amide derivative represented by formula (I) used in the present invention is produced, for example, according to the reaction formula shown below.

(CH2) n0H R2COOCH3(” ) R2−C−N−CH。(CH2) n0H R2COOCH3(”) R2-C-N-CH.

(CHz )nOCOR” C式中 R1,R2およびnは前記と同じ)すなわち、
グリシゾルエーテルとアミノアルコールから得られる化
合物(II)のアミン基を選択的にアシル化するか、又
は該化合物(It)をアシル化し、次いでエステル基を
選択的に加水分解することによって、アミド誘導体(I
)が製造される。
(CHz )nOCOR” C (where R1, R2 and n are the same as above), that is,
Amide derivatives can be obtained by selectively acylating the amine group of compound (II) obtained from glycisol ether and amino alcohol, or by acylating the compound (It) and then selectively hydrolyzing the ester group. (I
) is manufactured.

グリシゾルエーテルとアミノアルコールとの反応は、グ
リシゾルエーテルと3−アミノ−1−7’ロノ9ノール
、4−アミノ−1−ブタノール、5−アミノ−1−ペン
タノール、又は6−アミノ−1−ヘキサノールを、無溶
媒もしくはメタノール、エタノール、ソロノQノール、
イソゾロノQノール等の低級アルコール醪媒中、25〜
150℃で数十分〜5時間攪拌することによシ行なわれ
る。
The reaction between glycysol ether and amino alcohol is a reaction between glycysol ether and 3-amino-1-7' lono9ol, 4-amino-1-butanol, 5-amino-1-pentanol, or 6-amino-1 -Hexanol without solvent or methanol, ethanol, Solono Q-nol,
In a lower alcoholic medium such as isozorono Q-nol, 25~
This is carried out by stirring at 150°C for several tens of minutes to 5 hours.

化合物(II)のアミノ基のみをアシル化スるには、例
えば長鎖脂肪酸メチルエステルと化合物(If)を水酸
化アルカリ、炭酸アルカリ等の塩基の存在下、常圧= 
0.01 Torrの減圧下に25〜150℃で数十分
〜5時間反応させることにより行なわれる。
In order to acylate only the amino group of compound (II), for example, long-chain fatty acid methyl ester and compound (If) are reacted at normal pressure in the presence of a base such as alkali hydroxide or alkali carbonate.
The reaction is carried out under a reduced pressure of 0.01 Torr at 25 to 150°C for several tens of minutes to 5 hours.

化合物(I1)’を非選択的にアシル化するには、例え
ば長鎖脂肪酸ハライドと化合物(I1)をピリシン、第
三級アミン等の存在下に反応させることにより行なわれ
る。得られたアミド−エステル体のエステル基を選択的
に加水分解するには、水酸化アルカリ、炭酸アルカリ等
の塩基を用いて常法により行なわれる。
Non-selective acylation of compound (I1)' is carried out, for example, by reacting a long-chain fatty acid halide with compound (I1) in the presence of pyridine, a tertiary amine, or the like. Selective hydrolysis of the ester group of the obtained amide-ester is carried out by a conventional method using a base such as an alkali hydroxide or an alkali carbonate.

斯くして得られるアミド誘導体(I)の本発明皮膚外用
剤への配合量は、特に制限されないが、通常乳化型の皮
膚外用剤の場合には全組成の0.001〜50重量%C
以下単にチで示す)、特に0.1〜20%が好ましく、
マたスクワレン等の液状炭化水素を基剤とする油性の皮
膚外用剤の場合には1〜50%、特に5〜25%が好ま
しい。
The amount of the amide derivative (I) thus obtained to be incorporated into the skin external preparation of the present invention is not particularly limited, but in the case of an emulsion type skin external preparation, it is usually 0.001 to 50% by weight of C based on the total composition.
(hereinafter simply indicated by H), particularly preferably 0.1 to 20%,
In the case of oily skin preparations based on liquid hydrocarbons such as maasqualene, the amount is preferably 1 to 50%, particularly 5 to 25%.

本発明皮膚外用剤に配合される界面活性剤としては、非
イオン界面活性剤、陰イオン界面活性剤、両性界面活性
剤の倒れをも使用できるが、就中時に非イオン界面活性
剤が好適である。
As the surfactant to be incorporated into the external skin preparation of the present invention, nonionic surfactants, anionic surfactants, and amphoteric surfactants can also be used, but nonionic surfactants are particularly preferred. be.

非イオン界面活性剤としては、例えば?リオキシエチレ
ンアルキルエーテル、?リオキシエチレンアルキルフェ
ニルエーテル、?リオキシエチレン脂F[エステル、ソ
ルビタン脂肪酸エステル、?リオキシエチレンンルピタ
ン脂肪酸エステル、脂肪酸モノグリセライド、グリセリ
ルエーテル等が挙げられる。その中でも、次の一般式(
I)%式%) (式中、Rは炭素数8〜24のアルキル基を示す)で表
わされるグリセリルエーテル、就中Rが次式1式中、p
は4〜10の整数、qは5〜11の整数を示し、p+Q
=11〜17でp=7、q=3を頂点とする分布を有す
る) で表わされるものが特に好ましい。
What are some examples of nonionic surfactants? Lioxyethylene alkyl ether,? Lyoxyethylene alkyl phenyl ether,? Lioxyethylene fat F [ester, sorbitan fatty acid ester, ? Examples include lyoxyethylenelupitan fatty acid ester, fatty acid monoglyceride, and glyceryl ether. Among them, the following general formula (
I) Glyceryl ether represented by % formula %) (wherein R represents an alkyl group having 8 to 24 carbon atoms), in which R represents the following formula 1, p
represents an integer of 4 to 10, q represents an integer of 5 to 11, p+Q
= 11 to 17, with p = 7 and q = 3 as vertices) is particularly preferred.

界面活性剤の配合量は、全組成の0.01〜2゜チ、特
に0.1〜5%が好ましい。
The amount of surfactant to be blended is preferably 0.01 to 2%, particularly 0.1 to 5% of the total composition.

本発明の皮膚外用剤は、その使用形態において、乗用皮
膚外用剤と化粧料に大別される。
The external skin preparation of the present invention can be broadly classified into external skin preparations for riding and cosmetics in terms of its usage form.

薬用皮膚外用剤としては、例えば薬効成分を含有する各
檀軟膏剤を挙げることができる。軟膏剤としては、油性
基剤をペースとするもの、油/水、水/油型の乳化系基
剤をベースとするもののいずれであってもよい。油性基
剤としては、特に制限はなく、例えば植物油、動物油、
合成油、脂肪酸、及び天然又は合成のグリセライド等が
挙げられる。
Examples of medicated skin external preparations include various ointments containing medicinal ingredients. The ointment may be one based on an oily base, or one based on an oil/water or water/oil type emulsion base. There are no particular restrictions on the oily base, such as vegetable oil, animal oil,
Examples include synthetic oils, fatty acids, natural or synthetic glycerides, and the like.

また薬効成分としては、特に制限はなく、例えば鎮楠消
炎剤、鎮痒剤、殺菌消毒剤、収斂剤、皮膚軟化剤、ホル
モン剤等を必要に応じて適宜使用することかできる。
There are no particular limitations on the medicinal ingredients, and for example, anti-inflammatory agents, anti-pruritic agents, sterilizing agents, astringents, emollients, hormonal agents, etc. may be used as appropriate.

また、化粧料として使用する場合は、上記必須成分の他
に化粧料成分として一般に便用されている油分、保湿剤
、紫外線吸収剤、アルコール類、キレート剤、pH調整
剤、防腐剤、増粘剤、色素、香料等を任意に組合せて配
合することができる。
When used as a cosmetic, in addition to the above-mentioned essential ingredients, oils, moisturizers, ultraviolet absorbers, alcohols, chelating agents, pH adjusters, preservatives, thickeners, and thickeners that are commonly used as cosmetic ingredients should be added. Agents, dyes, fragrances, etc. can be blended in any combination.

化粧料としては、種々の形態、例えば水/油、油/水型
乳化化粧料、クリーム、化粧乳液、化粧水、油性化粧料
、口紅、ファウンデーション、皮膚洗浄剤、ヘアートニ
ック、1i髪剤、養毛剤、育毛剤等の皮膚化粧料とする
ことができる。
Cosmetics can be used in various forms, such as water/oil, oil/water type emulsified cosmetics, creams, cosmetic emulsions, lotions, oil-based cosmetics, lipsticks, foundations, skin cleansers, hair tonics, 1i hair preparations, and hair tonics. , skin cosmetics such as hair growth agents.

〔作用〕[Effect]

本発明皮膚外用剤における式(I)で示されるアミド誘
導体の作用機構の詳細は完全には解明されていないが、
これが角質細胞間に脂質膜を再構築して角質層の水分保
持機能を発揮するものと考えられる。
Although the details of the mechanism of action of the amide derivative represented by formula (I) in the skin external preparation of the present invention have not been completely elucidated,
It is thought that this rebuilds the lipid membrane between corneocytes and exerts the water retention function of the stratum corneum.

〔発明の効果〕〔Effect of the invention〕

本発明皮膚外用剤は、このような作用を有するアミド誘
導体(I)を含有するものであるため、肌あれに対して
優れた数置及び予防効果を発揮することができる。
Since the skin external preparation of the present invention contains the amide derivative (I) having such an effect, it can exhibit excellent anti-aging and preventive effects against rough skin.

〔実施例〕〔Example〕

次に実施例を挙げて説明する。 Next, an example will be given and explained.

参考例I N−(2−ヒドロキシ−3−ヘキサデシロキシゾロビル
)−N−3−ヒドロキシゾロビルへキサデカナミド〔式
(I)においてR1= Cl8H33、R”= C15
HH、n = 3のもの](Ia)の合成。
Reference Example I N-(2-hydroxy-3-hexadecyloxyzolobyl)-N-3-hydroxyzolobyl hexadecanamide [In formula (I), R1=Cl8H33, R''=C15
HH, n = 3] (Ia).

攪拌装置、滴下漏斗、温度計、還流冷却器およびN2導
入管を備えた200d4ツロフラスコに3−アミノ−1
−デロノQノール25. Of (0,333mol 
)およびエタノール509金入れ、N2界囲気下で80
℃に加熱攪拌しつつ、これにヘキサデシルグリシゾルエ
ーテル10. Of (0,034mot)をエタノー
ル30?に溶かした溶液を2時間かけて滴下した。滴下
終了後、更に同条件下で30分加熱攪拌したのち、蒸留
装置′i!cをとりつけエタノールおよび未反応の3−
アミノ−1−7’ロノ9ノールを減圧下に留去し、淡黄
色の固形物(Ha)12.5?を得た。得られた粗生成
物(Ila)のうち′147f (0,020mat相
当)をとり、水酸化カリウム0.056r’i加え、8
0℃/20Torrで加熱攪拌しつつ、これにヘキサデ
カン酸メチル5.42F(0,020mot)を1時間
かけて滴下した。滴下終了後更に同条件下1時間加熱攪
拌することにより淡黄色の粗生成物12.2Fを得た。
3-Amino-1 into a 200d4 Turow flask equipped with a stirrer, addition funnel, thermometer, reflux condenser and N2 inlet.
- Delono Q Nord 25. Of (0,333mol
) and ethanol 509 gold case, 80 under N2 atmosphere
Hexadecyl glycisol ether 10. Of (0,034mot) with ethanol 30? A solution dissolved in water was added dropwise over 2 hours. After the dropwise addition was completed, the mixture was further heated and stirred for 30 minutes under the same conditions, and then the distillation apparatus 'i! c, ethanol and unreacted 3-
Amino-1-7' lono9nol was distilled off under reduced pressure to give a pale yellow solid (Ha) of 12.5? I got it. '147f (equivalent to 0,020mat) of the obtained crude product (Ila) was taken, 0.056r'i of potassium hydroxide was added, and 8
Methyl hexadecanoate 5.42F (0,020 mot) was added dropwise thereto over 1 hour while heating and stirring at 0° C./20 Torr. After the dropwise addition was completed, the mixture was further heated and stirred for 1 hour under the same conditions to obtain a pale yellow crude product 12.2F.

これをヘキサ7120Fから1回、メタノール100?
から1回再結晶することにより無色粉末の目的化合物(
Ia)9.18Fを得た(全収率75%)。
This was done once from Hexa 7120F and 100 methanol?
By recrystallizing once from
Ia) 9.18F was obtained (total yield 75%).

m、p、   82.4〜83.4℃ IR(画一1)3250,2920,2854,160
5゜1470.1119 ”H−NMRO,87(t、6H)1.1−2.0(m
、56H)2.42(t、2H)3.2=4.4(m、
13H)元素分析 実測値(理論値) Cニア4.67%(74,57%) H:12.73%(I2,68%) N:2.21% (2,29%) 参考例2 N−(2−ヒドロキシ−3−ヘキサデシロキシプロビル
)−N−6−ヒドロキシヘキシルへキサデカナミド〔式
(I)においてR1: C16H33、R2= C15
H31、n = 6のもの)(Ib)の合成。
m, p, 82.4-83.4℃ IR (Standard 1) 3250, 2920, 2854, 160
5゜1470.1119”H-NMRO,87(t,6H)1.1-2.0(m
, 56H) 2.42(t, 2H) 3.2=4.4(m,
13H) Elemental analysis Actual value (theoretical value) Cnia 4.67% (74,57%) H: 12.73% (I2, 68%) N: 2.21% (2,29%) Reference example 2 N -(2-Hydroxy-3-hexadecyloxyprobyl)-N-6-hydroxyhexylhexadecanamide [In formula (I), R1: C16H33, R2=C15
Synthesis of H31, n = 6) (Ib).

攪拌装置、滴下漏斗、温度計、還流冷却器およびN2導
入管を備えた2 00 ml 4ツロフラスコに6−ア
ミノ−1−ヘキサノール58.0 ? (0,50mo
t)およびエタノール150tを入れ、N2雰囲気下で
80℃に加熱攪拌しつつ、これにヘキサデシルグリシゾ
ルエーテル15. O? (0,050mot)をエタ
ノール502に泪かした溶液を1時間かけて滴下した。
58.0 ml of 6-amino-1-hexanol in a 200 ml 4 flask equipped with a stirrer, addition funnel, thermometer, reflux condenser and N2 inlet. (0,50mo
t) and 150 t of ethanol, and while heating and stirring at 80°C under N2 atmosphere, 15.t of hexadecyl glycisol ether was added. O? A solution of (0,050 mot) dissolved in ethanol 502 was added dropwise over 1 hour.

滴下終了後更に同条件下で30分加熱攪拌したのち、蒸
留装置をとりつけ、エタノール及び未反応の6−アミノ
−1−ヘキサノールを減圧下に留去し、淡黄色の固形物
(Ilb)15.8Fを得た。得られた粗生成物のうち
、8.3F(0,020mot相尚)ヲとり、塩化メチ
レン200m1に溶解し、ピリシン4.8 F (0,
06mot)を加える。水冷下に塩化ヘキサデカノイル
16.FM’(0,06mot)を約30分かけて滴下
し、滴下終了後室温で1時間攪拌した。反応物を水洗し
てビリシン塩酸塩を除去し、溶媒を留去することにより
、アミド−エステル体(l[1b)22.6Fを得た。
After the dropwise addition was completed, the mixture was further heated and stirred for 30 minutes under the same conditions, and then a distillation apparatus was attached, and ethanol and unreacted 6-amino-1-hexanol were distilled off under reduced pressure to obtain a pale yellow solid (Ilb) 15. I got 8F. Of the obtained crude product, 8.3 F (0,020 mot phase) was taken, dissolved in 200 ml of methylene chloride, and 4.8 F (0,0
06mot). Hexadecanoyl chloride 16. under water cooling. FM' (0.06 mot) was added dropwise over about 30 minutes, and after the addition was completed, the mixture was stirred at room temperature for 1 hour. The reaction product was washed with water to remove bilicin hydrochloride, and the solvent was distilled off to obtain amide-ester (l[1b) 22.6F.

ひきつづき、これを95チエタノール水溶液4009に
溶解し、水酸化カリウム2.24f(0,04at )
を加えて、50’Cで1時間加熱攪拌した。反応物から
クロロホルム可泪物を抽出し、シリカゲルフラッシュカ
ラムクロマトグラフィーで梢製することにより、無色粉
末の目的化合物(Ib) 9.Of (0,0138m
ot)を得た(全収率52.4%)。
Subsequently, this was dissolved in 95% ethanol aqueous solution 4009, and 2.24f (0.04at) of potassium hydroxide was added.
was added, and the mixture was heated and stirred at 50'C for 1 hour. The target compound (Ib) was obtained as a colorless powder by extracting the chloroform-soluble material from the reaction product and purifying it by silica gel flash column chromatography.9. Of (0,0138m
ot) was obtained (total yield 52.4%).

m−p−78,8〜 79.8 ℃ IR(d’)3334,2920,2854,1623
゜1467.1113 ”H−NFdRO,87(t、6H)1.2〜1.9(
m、62H)2.41(t、2H) 3.1〜4.3(
m、13H)元素分析 実測値(理論値) Cニア5.33%(75,28%) H:12.83%(I2,79%) N:2.09% (2,14%) 実施例1 参考例1,2およびこれに準じて得た化合物Ia−1i
を使用し、ワセリン/化合物(Ia ml1)= 3/
1  (ff1t比)の混合物c本発明品1)とワセリ
ン(比較品1)の下記方法による皮膚コンダクタンス及
び肌あれについて評価した。結果を第1表に示す。
m-p-78,8-79.8℃ IR(d')3334,2920,2854,1623
゜1467.1113 "H-NFdRO, 87 (t, 6H) 1.2 ~ 1.9 (
m, 62H) 2.41 (t, 2H) 3.1 to 4.3 (
m, 13H) Elemental analysis Actual value (theoretical value) Cnia 5.33% (75,28%) H: 12.83% (I2, 79%) N: 2.09% (2,14%) Example 1 Compound Ia-1i obtained according to Reference Examples 1 and 2 and the same
using vaseline/compound (Ia ml1) = 3/
The skin conductance and skin roughness of a mixture c (inventive product 1) and vaseline (comparative product 1) of 1 (ff1t ratio) were evaluated by the following method. The results are shown in Table 1.

(試験方法) 冬期に頬部に肌あれを起こしている20〜50才の女性
10名を被験者とし、左右の頬に異なる皮膚外用剤を2
週間塗布する。2週間の塗布が終了した翌日に次の項目
につき試験を行なった。
(Test method) Ten women between the ages of 20 and 50 who suffer from rough skin on their cheeks during the winter were used as subjects, and two different topical skin preparations were applied to their left and right cheeks.
Apply weekly. The next day after the two-week application was completed, the following tests were conducted.

(I)皮膚コンダクタンス 37℃の温水にて洗顔後、温度20℃、湿度40%の部
屋で20分間安静にした後、角質層の水分含有量を皮膚
コンダクタンスメータ(IBS社製)にて測定した。コ
ンダクタンス値は値が小さいほど皮膚は肌あれし、5以
下ではひどい肌あれである。一方この値が20以上であ
れば肌あれはほとんど認められない。
(I) Skin conductance After washing the face with warm water at 37°C and resting in a room with a temperature of 20°C and a humidity of 40% for 20 minutes, the water content of the stratum corneum was measured using a skin conductance meter (manufactured by IBS). . As for the conductance value, the smaller the value, the more rough the skin becomes, and when it is less than 5, the skin becomes severely rough. On the other hand, if this value is 20 or more, skin roughness is hardly observed.

(2)肌あれスコア 肌おれは肉眼で観測し、下記基準により判定した1、ス
コアは平均値で示した。
(2) Skin roughness score Skin roughness was observed with the naked eye and judged according to the following criteria: 1, and the score is shown as an average value.

以下余白 第1表 実施例2 参考例1.2およびこれに準じて得た化合物1a−1i
を用いて下記第2衆に示す組成の皮膚外用剤(乳化化粧
料)を製造し、その肌あれ改善効果を実施例1と同様の
方法により評価した。結果を第3表に示すっ 第3表 以上
Table 1 Example 2 Reference Example 1.2 and Compounds 1a-1i Obtained Accordingly
A skin external preparation (emulsified cosmetic) having the composition shown in Group 2 below was prepared using the following, and its effect on improving rough skin was evaluated in the same manner as in Example 1. The results are shown in Table 3.

Claims (1)

【特許請求の範囲】 1、次の一般式( I ) ▲数式、化学式、表等があります▼( I ) (式中、R^1は炭素数10〜26の直鎖若しくは分岐
鎖の飽和若しくは不飽和の炭化水素基を、R^2は炭素
数9〜25の直鎖若しくは分岐鎖の飽和若しくは不飽和
の炭化水素基を、nは3〜6の数を示す) で表わされるアミド誘導体を含有する皮膚外用剤。 2、次の一般式( I ) ▲数式、化学式、表等があります▼( I ) (式中、R^1は炭素数10〜26の直鎖若しくは分岐
鎖の飽和若しくは不飽和の炭化水素基を、R^2は炭素
数9〜25の直鎖若しくは分岐鎖の飽和若しくは不飽和
の炭化水素基を、nは3〜6の数を示す) で表わされるアミド誘導体及び界面活性剤を含有する皮
膚外用剤。
[Claims] 1. The following general formula (I) ▲ Numerical formulas, chemical formulas, tables, etc. ▼ (I) (In the formula, R^1 is a linear or branched saturated or straight chain having 10 to 26 carbon atoms. An amide derivative represented by an unsaturated hydrocarbon group, R^2 is a linear or branched saturated or unsaturated hydrocarbon group having 9 to 25 carbon atoms, and n is a number from 3 to 6). Contains external skin preparations. 2. The following general formula (I) ▲Mathematical formulas, chemical formulas, tables, etc.▼(I) (In the formula, R^1 is a straight chain or branched chain saturated or unsaturated hydrocarbon group having 10 to 26 carbon atoms. , R^2 is a linear or branched saturated or unsaturated hydrocarbon group having 9 to 25 carbon atoms, and n is a number of 3 to 6) and a surfactant. External skin preparation.
JP5127687A 1987-03-06 1987-03-06 External skin preparation Expired - Lifetime JPH0692293B2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP5127687A JPH0692293B2 (en) 1987-03-06 1987-03-06 External skin preparation
ES92115766T ES2077948T3 (en) 1987-03-06 1988-03-02 PREPARATION FOR EXTERNAL SKIN CARE.
DE3854275T DE3854275T2 (en) 1987-03-06 1988-03-02 External skin care preparation.
EP88103177A EP0282816B1 (en) 1987-03-06 1988-03-02 External skin care preparation
EP92115766A EP0534286B1 (en) 1987-03-06 1988-03-02 External skin care preparation
DE88103177T DE3884021T2 (en) 1987-03-06 1988-03-02 External skin care preparation.
US07/163,835 US4985547A (en) 1987-03-06 1988-03-03 External skin care preparation
US07/546,276 US5028416A (en) 1987-03-06 1990-06-29 External skin care preparation
US07/584,739 US5071971A (en) 1987-03-06 1990-09-19 External skin care preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5127687A JPH0692293B2 (en) 1987-03-06 1987-03-06 External skin preparation

Publications (2)

Publication Number Publication Date
JPS63216812A true JPS63216812A (en) 1988-09-09
JPH0692293B2 JPH0692293B2 (en) 1994-11-16

Family

ID=12882422

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5127687A Expired - Lifetime JPH0692293B2 (en) 1987-03-06 1987-03-06 External skin preparation

Country Status (1)

Country Link
JP (1) JPH0692293B2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282816A2 (en) * 1987-03-06 1988-09-21 Kao Corporation External skin care preparation
US6221371B1 (en) 1996-11-11 2001-04-24 Aekyung Industrial Co., Inc. Pseudoceramides, and dermatologic external preparations containing the same
JP2014189542A (en) * 2013-03-28 2014-10-06 Kao Corp Method for producing amide derivative
WO2018221603A1 (en) 2017-05-30 2018-12-06 花王株式会社 Water-in-oil emulsion composition
WO2018221602A1 (en) 2017-05-30 2018-12-06 花王株式会社 Water-in-oil emulsion composition
WO2019131987A1 (en) 2017-12-28 2019-07-04 花王株式会社 Lipid particle dispersion

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282816A2 (en) * 1987-03-06 1988-09-21 Kao Corporation External skin care preparation
US6221371B1 (en) 1996-11-11 2001-04-24 Aekyung Industrial Co., Inc. Pseudoceramides, and dermatologic external preparations containing the same
JP2014189542A (en) * 2013-03-28 2014-10-06 Kao Corp Method for producing amide derivative
WO2018221603A1 (en) 2017-05-30 2018-12-06 花王株式会社 Water-in-oil emulsion composition
WO2018221602A1 (en) 2017-05-30 2018-12-06 花王株式会社 Water-in-oil emulsion composition
WO2019131987A1 (en) 2017-12-28 2019-07-04 花王株式会社 Lipid particle dispersion

Also Published As

Publication number Publication date
JPH0692293B2 (en) 1994-11-16

Similar Documents

Publication Publication Date Title
EP0227994B1 (en) Amide derivative and external medicament comprising same
JP4358996B2 (en) External preparation composition
JPS63192703A (en) External agent for skin
US4032676A (en) N-polyhydroxyalkyl-amino acids, their manufacture and skin treating agents containing the same
KR100349043B1 (en) (poly)thiaalkynoic compounds and their derivatives, compositions comprising them and their use
JPH0517399A (en) Ester derivative and cosmetics containing the same derivative
KR940011454B1 (en) Amide derivatives and external medicament comprising same
JPS63216812A (en) Skin drug for external use
US3317382A (en) Substituted 5-phenylsalicylic acid compounds for the prevention and treatment of erythema
JPH0676358B2 (en) Amide derivative and external preparation for skin containing the same
JP2551471B2 (en) Glyceryl ether derivative and skin external preparation containing the same
JPH0692296B2 (en) External skin preparation
JPH078844B2 (en) Amide derivative and external preparation for skin containing the same
JP3073813B2 (en) Cosmetics
JP4112741B2 (en) Moisturizer
JPH06145123A (en) Amide derivative and its production intermediate, and skin external preparation containing the amide derivative
JPS63227514A (en) Dermatic drug for external application
JPS63218609A (en) External drug for skin
JPH0763613B2 (en) Water-in-oil emulsion composition
JPH04217610A (en) Skin external preparation
JPH0565485B2 (en)
JP2704759B2 (en) Glyceryl ether derivative and external preparation for skin containing the same
JPS62158204A (en) Hair growth agent
JPH06100433A (en) Agent for inhibiting tyrosinase activity
JPH02306949A (en) Amide derivative and external preparation for skin containing the same

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term